Top Stories
Proceeds will go toward building scalable, “AI-first” translational and clinical development infrastructure as the company moves its drug candidates toward the clinic.
The funding will be used to advance the dual-targeting bispecific complement engager (BiCE) molecule COM002 toward the clinic.
The POLARIS-AD study achieved its main goal in patients not taking an acetylcholinesterase inhibitor or memantine, but failed to produce a similar effect in the overall trial population.
The biotech is looking to develop engineered antibodies that target the transferrin receptor in bone marrow to deliver therapeutic payloads.
The approval is backed by positive Phase III REPLENISH data showing sustained remission and lower steroid use.
Conference News
In real-world German data from the Bayer-led mODIficATTR study, acoramidis was associated with a 23% lower risk of ODI, an early marker of worsening HF, versus tafamidis (adjusted HR 0.77; 95% CI 0.61...
Meanwhile, whether or not Wilserdly is approved in Europe, at least as a later-line therapy, will depend on positive overall survival data which could read out in the middle of next year.
FirstWord spoke with enGene CEO Ron Cooper and Chief Medical Officer Erik Goluboff about maturing data for the investigational bladder cancer therapy detalimogene voraplasmid — a non-viral gene therapy being studied in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMI
STAFFORD, Texas, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM...
- Efficient screening processes may reduce participant and site burden in clinical trials -PURCHASE, N.Y., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (N...





